



Overview

In 2000, the world celebrated the first complete draft of the human genome. Less well known that year, SomaLogic was founded to take on a much harder technical challenge that held even greater promise for transforming healthcare: The ability to go beyond genes to measure the time-based changes thousands of human proteins affordably, reliably and repeatedly. Although the human genomic blueprint can provide clues about future potential health issues, proteins uniquely provide information about current health status –and its trajectory – in real time.

SomaLogic set out to (1) invent and develop an entirely new human protein measurement technology, then (2) apply that technology to the management of human health and wellness. It took SomaLogic scientists more than a dozen years and nearly \$500M to complete the first task, but the technology tools they built (collectively called the “SomaScan® Platform”) is unprecedented and unparalleled in the history of the life sciences.

The SomaScan® Platform simultaneously measures thousands of human proteins across a massive concentration range in a small volume of biological sample, and detects even very small changes in those concentrations that in turn can reveal the presence of disease (including in very early stages), compromised nutritional and fitness status, and even the physiological effects of external interventions such as drug treatment. We continue to improve the scale and cost of the technology, but the basic challenge of building it has been met. In addition, we have built the bioinformatics (including AI/ML) capacity and resources needed to translate these large protein data sets into useful health-related information.

We are now focusing on succeeding at the second task: bringing this technology and its translation to bear on multiple different aspects of human health via the healthcare marketplace. To date, we have focused primarily on providing otherwise unattainable protein data to hundreds of biopharma and academic customers and collaborators to understand the basic biology of diseases of interest, and to help them build new therapeutic and even diagnostic strategies. We have also used the valuable protein-related disease knowledge base we are building from this work to market our own diagnostic tests (SomaSignal™ tests), beginning with areas of significant unmet needs such as cardiometabolic disease. Although we have a pipeline of over 100 tests in planning, we are working towards the day when the results from all of these individual tests can be delivered out of a single sample.

Our SomaScan® Platform technology is “disease-agnostic,” allowing us to address virtually every human disease and condition. For example, in recognition of the urgent needs for deeper knowledge of SARS-CoV-2 infection and COVID-19 disease, we have turned our work towards understanding the protein-based underlying biology of virus-host interactions, including identifying who is most at risk for developing serious disease, and how to measure if a candidate drug or vaccine is working before a full-length traditional clinical trial can be conducted (i.e., based on protein responses to the intervention).

SomaLogic was founded and remains headquartered in Boulder, Colorado. We have 195 employees as of December 1, 2019.